173 results on '"Scott Wadler"'
Search Results
52. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma
- Author
-
Jacob Cynamon, Peter H. Wiernik, Donald J. Martinelli, Hilda Haynes, Alla M. Rozenblit, Scott Wadler, Ronald Kaleya, and Curtis W. Bakal
- Subjects
Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Colorectal cancer ,business.industry ,medicine.medical_treatment ,medicine.disease ,Surgery ,Recurrent Colorectal Carcinoma ,Metastasis ,Oncology ,Fluorouracil ,medicine ,Radiology ,Embolization ,Abscess ,business ,medicine.drug ,Liver abscess - Abstract
Background Second-line therapy of patients with colorectal cancer metastatic to the liver is unsatisfactory. One alternative to systemic treatment is therapy directed locoregionally. Methods Twenty-four patients with unresectable colorectal cancer with bulky liver metastases who had failed prior systemic therapy were randomized to treatment with either embolization or chemoembolization. For the embolization group, particulate transcatheter polyvinyl alcohol (PVA) (150-250-microns particles) mixed with full-strength iodinated radiographic contrast was administered under direct fluoroscopic control. In patients randomized to chemoembolization, 5-fluorouracil (750 mg/m2) and recombinant alpha-2a-interferon (Roche Laboratories, Nutley, NJ) (9-MU) were thoroughly mixed into the PVA contrast suspension. Study end points were response to therapy and survival. Results Of 24 patients, 13 were randomized to chemoembolization and 11 to embolization therapy. All were assessable for toxicity, response, and complications. Among the first 13 patients treated initially, a suppurative abscess developed in one patient, who died. Eleven subsequent patients were pretreated with oral and intravenous antibiotics without further infectious complications. Five patients had hemorrhagic complications, two of which were serious. The treatment was otherwise well tolerated, with most patients experiencing transient pain, fevers, and elevations in leukocyte counts and liver enzymes, which resolved spontaneously. Computed tomography scans of the liver were used to assess patient response to therapy. There were 6 responders (25%) among the 24 patients treated. No differences in response to treatment or survival between the embolization and chemoembolization groups were noted. With a median follow-up of more than 12 months, the median survival was 9.3 months from the time of embolization therapy. Conclusions Embolization and chemoembolization therapy appear to have antitumor activity as second-line therapy in patients with colorectal carcinoma with bulky liver metastases. Although generally well tolerated, complications of this therapy may be severe. The addition of further patients to this trial will allow a rigorous comparison of embolization alone versus embolization with chemotherapy.
- Published
- 1994
53. New barriers to ventricular invasion in paraglottic laryngeal cancer
- Author
-
Robin J. Mitnick, Jacqueline A. Bello, Carl E. Silver, John S. Rubin, Scott Wadler, Jonathan J. Beitler, Panna S. Mahadevia, and Bhadrasain Vikram
- Subjects
Larynx ,Cancer Research ,education.field_of_study ,Pathology ,medicine.medical_specialty ,Elastic Barrier ,Conus elasticus ,Quadrangular membrane ,business.industry ,Cancer ,Autopsy ,Anatomy ,Thyroid cartilage ,medicine.disease ,medicine.anatomical_structure ,Oncology ,Ventricle ,medicine ,education ,business - Abstract
Background. Anatomic barriers to the spread of laryngeal cancer include the conus elasticus, the quadrangular membrane, and the thyroid cartilage. It has been speculated that an elastic barrier surrounds and protects the ventricle. Methods. The authors studied the microanatomic patterns of spread of 17 cases of patients who had laryngeal cancer with paraglottic disease and confirmed their findings by examining normal autopsy specimens. Results. Five patients of the seventeen cases showed no ventricular mucosal involvement despite extensive paraglottic disease. Both an inner, central, subepithelial periventricular elastic barrier, and a more peripheral periventricular elastic membrane barrier were identified; the latter was in continuity with the conus elasticus and quadrangular membrane
- Published
- 1994
54. Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer
- Author
-
Edward S. Greenwald, Lorraine Cazenave, Joseph A. Sparano, Alla M. Rozenblit, Ronald Kaleya, Peter H. Wiernik, Scott Wadler, and Laura Tenteromano
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_treatment ,Echinomycin ,Adenocarcinoma ,Toxicology ,chemistry.chemical_compound ,medicine ,Humans ,Pharmacology (medical) ,Dexamethasone ,Aged ,Aged, 80 and over ,Pharmacology ,Chemotherapy ,business.industry ,Diphenhydramine ,Middle Aged ,Survival Analysis ,Regimen ,Treatment Outcome ,Oncology ,chemistry ,Anesthesia ,Toxicity ,Vomiting ,Female ,Premedication ,Neoplasm Recurrence, Local ,medicine.symptom ,Colorectal Neoplasms ,business ,medicine.drug - Abstract
Echinomycin is a novel bifunctional intercalating agent derived from Streptomyces echinatus. A phase II clinical trial of echinomycin in patients with advanced, measurable colorectal cancer was initiated to determine the efficacy and toxicities of this agent. Echinomycin, 1.5 mg/m2, was given initially as a 30- to 60-min infusion every 4 weeks. After 4 episodes of anaphylaxis had occurred among the first 14 patients, the schedule was changed to a 24-h infusion, and an additional 16 patients were treated on this schedule. Treatment was given every 3 weeks. A total of 30 patients were eligible and evaluable; there were 3 (10%; 90% confidence interval, 3%-23%) clinical responses lasting 3, 3+, and 12 months, respectively. The most serious toxicity encountered was anaphylaxis, which occurred in 5 patients, although with no serious sequelae. A premedication regimen with dexamethasone, diphenhydramine, and cimetidine and a change of the duration of the infusion to 24 h reduced the incidence of this complication. Grade 2-3 vomiting occurred among earlier patients treated; however, with the 24-h schedule this toxicity was substantially reduced. The sole important case of hematologic toxicity was a single patient with grade 3 thrombocytopenia. Echinomycin employed in this dose and schedule had modest activity against colorectal cancer, comparable with that observed with 5-fluorouracil. Further studies in patients with gastrointestinal malignancies using a 24-h infusion with a dexamethasone premedication regimen similar to that employed prior to administration of taxol may be warranted.
- Published
- 1994
55. Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon
- Author
-
Edward L. Schwartz and Scott Wadler
- Subjects
Pharmacology ,Cancer Research ,Catabolism ,Chemistry ,medicine.medical_treatment ,Cancer ,Antineoplastic Agents ,Drug Synergism ,Drug interaction ,Toxicology ,medicine.disease ,Cytokine ,Oncology ,Mechanism of action ,Interferon ,medicine ,Animals ,Humans ,Cytotoxic T cell ,Pharmacology (medical) ,Interferons ,medicine.symptom ,Cytotoxicity ,medicine.drug - Abstract
Biochemical modulation of cytotoxic cancer chemotherapeutic agents is one means of enhancing the activity and selectivity of antitumor drugs. Traditionally this approach has utilized detailed information regarding a particular enzymatic reaction or biochemical pathway to develop potential modulating agents. In contrast, the reported clinical therapeutic activity of IFN in combination with cytotoxic agents has prompted a reexamination of the biochemical actions of the cytokine. Interferon elicits a number of cellular actions that might contribute to its pharmacologic activity, including both direct antitumor effects and host-mediated actions. The best understood are those related to the cytotoxicity of the fluoropyrimidine antimetabolites and include enzymatic reactions involved in fluoropyrimidine metabolic activation, catabolism, and interaction with its target enzyme. However, even in this instance, a mechanistic association of a specific pharmacologic action with therapeutic activity remains to be determined. These studies demonstrate that cytokines and other biologic agents may exert specific biochemical modulations that augment (or potentially attenuate) the activity of the cytotoxic chemotherapeutic agents.
- Published
- 1994
56. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation
- Author
-
Avi I. Einzig, E. L. Schwartz, Peter H. Wiernik, Scott Wadler, Zhihang Lu, R. B. Diasio, Ruiwen Zhang, and Joseph A. Sparano
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,Alpha interferon ,Pharmacokinetics ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Mucositis ,Humans ,Medicine ,Drug Interactions ,Infusions, Intravenous ,Interferon alfa ,Aged ,Chemotherapy ,business.industry ,Interferon-alpha ,Middle Aged ,medicine.disease ,Treatment Outcome ,Oncology ,Fluorouracil ,Toxicity ,Conventional PCI ,Female ,business ,Nuclear medicine ,medicine.drug - Abstract
PURPOSE To determine the maximum-tolerable dose (MTD) of fluorouracil (5-FU) administered as a low-dose, prolonged continuous intravenous infusion (PCI) plus interferon-alfa (IFN-alpha) that would permit treatment for at least 28 consecutive days, and to determine the effect of IFN-alpha on 5-FU pharmacokinetics. PATIENTS AND METHODS Twenty-six assessable patients with advanced cancer received low-dose PCI 5-FU (150, 200, 250, and 300 mg/m2/d) plus IFN-alpha, 5 x 10(6) IU/m2 administered subcutaneously (SC) at hour 48 of the 5-FU infusion, then thrice weekly thereafter in cohorts of at least three patients. Treatment continued until treatment-limiting toxicity (TLT) developed, such as mucositis, diarrhea, or fatigue. Escalation to the next 5-FU dose level occurred if none of three or zero to two of six patients developed TLT before day 28. Quantitation of plasma 5-FU concentration by high-performance liquid chromatography was performed in 15 patients. Data were standardized using the Cosinor method and compared before and after IFN-alpha administration using the paired t test. RESULTS The mean number of days of continuous 5-FU therapy for patients receiving 150, 200, 250, and 300 mg/m2/d of 5-FU plus IFN alfa-2a (IFN-alpha 2a) was 75, 54, 37, and 22 days, respectively. The MTD of PCI 5-FU by our criteria that could be combined with IFN-alpha was 250 mg/m2/d. Comparison of the standardized pharmacokinetic data showed no significant effect of IFN-alpha on plasma 5-FU concentration, and no alteration of the normal circadian variation in plasma 5-FU concentration that was evident before IFN-alpha administration. Objective response occurred in patients with adenocarcinoma of the pancreas (n = 3), kidney (n = 2), and lung (n = 1). CONCLUSION IFN-alpha substantially enhanced the gastrointestinal toxicity of low-dose PCI 5-FU without affecting 5-FU pharmacokinetics, contrary to previous reports using alternative 5-FU schedules in which IFN-alpha-related enhancement of 5-FU toxicity was attributable to reduced 5-FU clearance. Our findings suggest that under certain conditions, mechanisms other than altered 5-FU pharmacokinetics may be responsible for the ability of IFN-alpha to enhance the toxic effects of 5-FU.
- Published
- 1993
57. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study
- Author
-
Frances McGill, Carmel Cohen, Alia Rozenblit, Carolyn D. Runowicz, Hilda Haynes, Jonathan J. Beitler, Scott Wadler, Gary L. Goldberg, James Speyer, and John Rubin
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Brachytherapy ,Urology ,Uterine Cervical Neoplasms ,Pilot Projects ,Gynecologic oncology ,Adenocarcinoma ,Drug Administration Schedule ,Amifostine ,medicine ,Carcinoma ,Humans ,Radiation Injuries ,Hearing Disorders ,Aged ,Cisplatin ,Chemotherapy ,Leukopenia ,business.industry ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Surgery ,Radiation therapy ,Oncology ,Carcinoma, Squamous Cell ,Female ,Azotemia ,medicine.symptom ,business ,medicine.drug - Abstract
PURPOSE A phase I trial of WR2721 was initiated to determine the maximal safe dose for incorporation into a consecutive 5-day schedule of cisplatin administered concurrently with radiation therapy in patients with cervical cancer. PATIENTS AND METHODS WR2721 was administered at 340 to 910 mg/m2/d immediately before cisplatin. Cisplatin was administered at 20 mg/m2/d for 5 days every 3 weeks in combination with external-beam radiation therapy and at 100 mg/m2 after each brachytherapy treatment. Pelvic radiation consisted of external-beam therapy to a dose of 39.6 Gy, followed by brachytherapy with cesium 137 tandem and ovoid insertions to deliver 80 Gy to point A and 55 Gy to point B. RESULTS Twenty patients were enrolled; 19 were assessable. The dose-limiting toxicity of WR2721 was hypotension. No patients developed serious sequelae, but hypotension required a reduction in the dose of WR2721 at the highest dose level tested. The major grade 3 or 4 toxicities included transient azotemia (five of 19), leukopenia (nine of 19), vomiting (four of 19), and neurotoxicity (two of 19). One patient experienced an anaphylactic reaction to cisplatin. CONCLUSION The recommended dose of WR2721 administered in conjunction with cisplatin on a daily x 5 schedule plus radiation therapy is 825 mg/m2/d for 5 days.
- Published
- 1993
58. Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon
- Author
-
Henry J. Katz, Alla M. Rozenblit, Scott Wadler, Stanley C. Fell, Hilda Haynes, Ronald Kaleya, and Peter H. Wiernik
- Subjects
Cancer Research ,medicine.medical_specialty ,Epithelioma ,Performance status ,Esophageal disease ,business.industry ,Carcinoma in situ ,medicine.disease ,Gastroenterology ,Surgery ,medicine.anatomical_structure ,Oncology ,Renal cell carcinoma ,Internal medicine ,Carcinoma ,medicine ,Adenocarcinoma ,Esophagus ,business - Abstract
Background Combinations of 5-fluorouracil (5FU) and recombinant alfa-2a-interferon (IFN) are synergistic in vitro and have demonstrated activity in colorectal carcinoma, renal cell carcinoma, and urothelial tumors. Methods A Phase II trial of the combination of 5FU, 750 mg/m2 daily x 5 followed by weekly bolus therapy, and IFN, 9 MU subcutaneously three times per week, was initiated in patients with esophageal carcinomas. Patients were required to have biopsy-proven squamous cell or adenocarcinoma of the esophagus, locally advanced or metastatic disease beyond the scope of surgical resection, and adequate performance status, renal, hepatic, and bone marrow function. Results Twenty-one patients were enrolled; one patient was inevaluable for response because he had received prior chemotherapy, but was evaluated for toxicity. Eleven patients had metastatic disease, and 10 had locally advanced disease. Thirteen patients had squamous cell carcinoma and 8 adenocarcinoma. Toxicities were acceptable with no serious diarrhea and only two cases of serious stomatitis, although a greater than expected incidence of neurologic toxicity was observed. There were five responders (25%) including two patients with advanced or locally advanced disease rendered pathologically free of disease. One patient, initially considered surgically unresectable, was able to undergo a total thoracic esophagectomy after responding to treatment with 5FU/IFN, at which time only a single microscopic focus of carcinoma in situ was found. She remains alive and free of disease at 18+ months. A second patient who presented with metastatic disease and nearly complete obstruction of the esophagus regained normal swallowing function after treatment with 5FU/IFN; rebiopsy of all lesions revealed the patient to be pathologically free of disease. He survived over 2 years. Conclusions This regimen employing a single cytotoxic agent has activity in esophageal carcinoma. Strategies employing biochemical modulation deserve additional investigation in the treatment of esophageal carcinoma.
- Published
- 1993
59. High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (radiation therapy oncology group protocol 8801)
- Author
-
M. J. Gallagher, T. Peters, J. Pederson, Scott Wadler, R.U. Komaki, R. W. Byhardt, Stanley E. Order, and A. Herskovic
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Pancreatic disease ,business.industry ,medicine.medical_treatment ,medicine.disease ,Primary tumor ,Surgery ,Radiation therapy ,Pancreatic tumor ,Fluorouracil ,Internal medicine ,medicine ,Mucositis ,Adenocarcinoma ,business ,medicine.drug - Abstract
Adenocarcinoma of the pancreas is an extremely malignant neoplasm with a particular propensity to spread to the liver. In an effort to combine chemotherapy with high-dose local irradiation plus a modest dose of irradiation to suspected (subclinical) hepatic metastasis, patients with unresectable pancreatic carcinomas with no known distant metastasis were treated on a prospective multi-institutional Radiation Therapy Oncology Group (RTOG) Phase I/II trial. High total dose continuous radiation therapy to the pancreas (6120 cGy in 34 fractions over 7 weeks) and simultaneous prophylactic hepatic irradiation (PHI, 2340 cGy in 13 fractions for the last 2.5 weeks) were combined with administration of 5-fluorouracil 1000 mg/m2/day (maximum, 1500 mg) by intravenous continuous infusion for 5 days starting on day 1 and repeated on day 30 for 5 days, followed by a dose of 600 mg/m2 as a weekly bolus injection starting during week 9 for 6 months. In 18 months, 81 patients were enrolled in the study; 79 were evaluable with a minimum potential follow-up of 8.2 months. The patients ranged in age from 32 to 75 years (median, 64 years). Karnofsky performance status was 80 to 100 in 74% of patients. The tumor was confined to the head of the pancreas in 72% of patients. The planned radiation therapy for the pancreas was completed in 87% of patients, 80% received the planned PHI, and 85% completed the first two cycles of chemotherapy. Seventy-five percent of patients completed both treatments according to the protocol. Most patients who did not complete both treatments had tumor progression or refused additional therapy. During all cycles of chemotherapy and radiation therapy, 2 patients died of complications (Grade 5, 1 hepatic and 1 infection), 9 had life-threatening reactions (Grade 4, 7 hematologic, 1 neurologic, and 1 mucositis), and 31 patients had severe effects (Grade 3) according to the RTOG toxicity scale. Overall hepatic metastasis was documented in 32% (13% as the first site of failure), persistent or progressive pancreatic tumor was evident in 73%, and abdominal and extra-abdominal spread were reported in 27% and 8% of patients, respectively. Eighty percent (63 patients) died (median survival, 8.4 months). Although this study suggests that PHI may reduce the frequency of hepatic metastasis, failure to control the primary tumor and intraabdominal spread remain overwhelming.
- Published
- 1992
60. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells
- Author
-
Carolyn J. O'Connor, Mark A. Hoffman, Scott Wadler, and Edward L. Schwartz
- Subjects
Radioisotope Dilution Technique ,medicine.medical_specialty ,Thymidine kinase activity ,Adenosine ,medicine.medical_treatment ,Biophysics ,Pyrimidine-nucleoside phosphorylase ,Alpha interferon ,Interferon alpha-2 ,Biology ,Tritium ,Biochemistry ,Cell Line ,Interferon ,Internal medicine ,medicine ,Humans ,RNA, Neoplasm ,Cytotoxicity ,Molecular Biology ,Biotransformation ,Interferon alfa ,Interferon-alpha ,DNA, Neoplasm ,Cell Biology ,Recombinant Proteins ,Kinetics ,Cytokine ,Endocrinology ,Uridine phosphorylase ,Colonic Neoplasms ,Cancer research ,Fluorouracil ,Thymidine ,medicine.drug - Abstract
Interferon-alpha (IFN alpha) increases the cytotoxicity of 5-fluorouracil (FUra) in vitro, and the combination has clinical efficacy against advanced colorectal cancer. IFN alpha treatment of HT-29 colon carcinoma cells induced a greater than two-fold increase in the intracellular levels of the active metabolite of FUra, FdUMP. Using cell extracts from HT-29 cells and FUra as substrate, IFN alpha produced a 1.9- and 8.7-fold increase, respectively, in the activities of uridine phosphorylase and pyrimidine nucleoside phosphorylase (PyNP). Furthermore, the effect was selective for the conversion of FUra to FdUMP, as IFN alpha did not increase the cellular levels of FUTP, nor did it change the extent of incorporation of FUra into RNA (or DNA). IFN alpha also had no effect on thymidine kinase activity, the second step in the activation of FUra. Hence the effect of IFN alpha on PyNP activity is likely a critical biochemical event that modulates the cytotoxicity of FUra.
- Published
- 1992
61. Back to the Future: New Theories on 5-Fluorouracil/Interferon Interactions
- Author
-
Scott Wadler
- Subjects
Cancer Research ,Oncology ,Interferon ,Chemistry ,Fluorouracil ,medicine ,Cancer research ,General Medicine ,medicine.drug - Published
- 1992
62. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study
- Author
-
John M. Kirkwood, N Petrelli, Scott Wadler, Michael B. Atkins, and Barry C. Lembersky
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Alpha interferon ,Interferon alpha-2 ,Bolus (medicine) ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Carcinoma ,Humans ,Interferon alfa ,Aged ,Aged, 80 and over ,Chemotherapy ,business.industry ,Interferon-alpha ,Middle Aged ,medicine.disease ,Survival Analysis ,Recombinant Proteins ,Clinical trial ,Fluorouracil ,Drug Evaluation ,Female ,Colorectal Neoplasms ,business ,medicine.drug - Abstract
In a pilot clinical trial, treatment of patients with advanced colorectal carcinoma with the combination of fluorouracil (5FU) and recombinant interferon alfa-2a (IFN) resulted in objective tumor regression in 62% of patients. To confirm these findings in a multiinstitutional setting, a phase II clinical trial was initiated by the Eastern Cooperative Oncology Group (ECOG) in 1989. The treatment regimen was identical to that used in the earlier study: 5FU 750 mg/m2/d for 5 days as a continuous infusion followed by weekly outpatient bolus therapy and IFN 9MU subcutaneously beginning day 1 and administered three times per week. Doses were modified for gastrointestinal, hematologic, and neurologic toxicity and for fatigue, similarly to those used in the previous pilot trial. Thirty-eight patients were registered; 36 are evaluable for response (one lost to follow-up and one with nonmeasurable disease). All patients had metastatic or locally recurrent disease beyond the scope of resection; 31 of 38 had liver metastases, and 20 of 38 had two or more sites of involvement. Eight patients had grade 4 toxicities, including sepsis (nonneutropenic) (one), watery diarrhea (two), and granulocytopenia (six). Grade 3 neurologic toxicities were observed in two (5%) patients and included slurred speech and gait disturbance. Objective response was 42% (95% confidence interval [Cl], 27% to 58%), including one clinical complete responder and 14 partial responders. Among the responding patients, the median time to treatment failure was 8 months. Two patients remain on treatment at 10+ and 16+ months: median survival has not been reached. The results of this multiinstitutional trial suggest that the addition of IFN to 5FU enhances the objective response rates achieved in patients with advanced colorectal carcinoma and that the toxicities of this regimen are acceptable.
- Published
- 1991
63. Working conference on biomodulator and chemotherapy combination therapies
- Author
-
Richard Pazdur, Scott Wadler, Malcolm S. Mitchell, Thomas D. Brown, and Geoffrey R. Weiss
- Subjects
Pharmacology ,Oncology ,medicine.medical_specialty ,Chemotherapy ,business.industry ,Internal medicine ,medicine.medical_treatment ,Pharmacology toxicology ,medicine ,Pharmacology (medical) ,business - Published
- 1991
64. Molecular targeting in pancreatic cancer
- Author
-
Scott Wadler
- Subjects
Pharmacology ,Clinical Trials as Topic ,Cetuximab ,Neovascularization, Pathologic ,business.industry ,medicine.medical_treatment ,Antibodies, Monoclonal ,Antineoplastic Agents ,General Medicine ,Cell cycle ,medicine.disease ,Targeted therapy ,Pancreatic Neoplasms ,Proteasome ,Epidermal growth factor ,Pancreatic cancer ,Reolysin ,medicine ,Cancer research ,Animals ,Humans ,Epigenetics ,business ,medicine.drug ,Signal Transduction - Abstract
The mortality and morbidity of tumors of the upper GI tract are formidable with incidence and mortality nearly the same. Therefore, better therapies are necessary, and these are generally molecularly targeted therapies. This chapter focuses on the treatment of pancreatic cancer with targeted therapy. Important cellular pathways are reviewed, including signal transduction, proteasome inhibition, cell cycle, anti-angiogenesis pathways, immunologic therapies, viral therapy, epigenetic therapies and microarray analysis. Signal transduction pathways include epidermal growth factor receptors, such as cetuximab and Tarceva, as well as other less well-defined pathways. Proteasome inhibition includes inhibition of the 26S proteasome with PS-341. Cell cycle therapies include inhibitors of all the proteins involved in pushing the cell through the cell cycle. Viral therapies mainly cover the adenoviruses, like ONYX-015, and Reolysin, a type 3 serotype Dearing strain with little pathogenicity. Immunological therapies include cytokines, vaccines and cell-based therapies. Epigenetic therapies are mainly centered around histone deacetylases. Microarray analysis analyzes expression of thousands of genes to create a tumor profile, mainly for prognosis or prediction. Various promising treatment strategies are reviewed in terms of treatment with molecularly-guided therapies. Complications of therapy, particularly rash and thrombosis are reviewed.
- Published
- 2008
65. Molecular Targeting in Oncology
- Author
-
Scott Wadler, Karen H. Antman, and Howard L. Kaufman
- Subjects
Oncology ,medicine.medical_specialty ,Molecular targeting ,Pharmacotherapy ,business.industry ,Internal medicine ,Medicine ,business - Abstract
Molecular targeting in oncology , Molecular targeting in oncology , کتابخانه دیجیتال جندی شاپور اهواز
- Published
- 2008
66. Crescentic glomerulonephritis associated with prostatic carcinoma: Evidence of immune-mediated glomerular injury
- Author
-
Leonarda B. Sablay, Ralph P. Mennemeyer, Lloyd P. Haskell, Mary Jean Fusco, and Scott Wadler
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Acid Phosphatase ,Adenocarcinoma ,Immunoenzyme Techniques ,Glomerulonephritis ,Immune system ,Antigens, Neoplasm ,Prostate ,Biomarkers, Tumor ,medicine ,Carcinoma ,Humans ,Aged ,Aged, 80 and over ,Staining and Labeling ,biology ,business.industry ,Crescentic glomerulonephritis ,Acid phosphatase ,Prostatic Neoplasms ,General Medicine ,Prostate-Specific Antigen ,medicine.disease ,Prostate-specific antigen ,medicine.anatomical_structure ,biology.protein ,business - Published
- 1990
67. Molecular Targeting in Upper Gastrointestinal Malignancies
- Author
-
Scott Wadler
- Subjects
Oncology ,medicine.medical_specialty ,education.field_of_study ,Angiogenesis ,business.industry ,medicine.medical_treatment ,Population ,Cancer ,medicine.disease ,Targeted therapy ,Clinical trial ,medicine.anatomical_structure ,Internal medicine ,Pancreatic cancer ,medicine ,Pancreas ,Stomach cancer ,education ,business - Abstract
Tumors of the upper gastrointestinal tract (GI) are not common but represent a significant clinical challenge. Treatment of locally advanced and metastatic tumors of the upper GI tract, liver and pancreas has met with limited success using standard cytotoxic agents. The development of agents that block signal transduction pathways, cell cycle proteins, proteosomal degredation, angiogenesis and immunologic-based approaches are being tested in this group of tumors. These studies have better defined the toxicity profiles of these agents but have resulted in limited successful clinical responses. The pre-clinical and preliminary clinical trial results will be reviewed and some of the problems with targeted therapy in the upper GI tract cancer population will be discussed.
- Published
- 2007
68. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study
- Author
-
Heinz-Josef Lenz, Nancy E. Kemeny, Mithat Gonen, Leonard B. Saltz, Ellen Hollywood, Marcus Quinones, Scott Wadler, Helen X. Chen, Paulo M. Hoff, Hedy L. Kindler, Meroe Morse, and Howard S. Hochster
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Randomization ,Bevacizumab ,Colorectal cancer ,Phases of clinical research ,Cetuximab ,Antibodies, Monoclonal, Humanized ,Irinotecan ,Loading dose ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Neoplasm Metastasis ,neoplasms ,Aged ,Aged, 80 and over ,business.industry ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,digestive system diseases ,Surgery ,Clinical trial ,Treatment Outcome ,Disease Progression ,Camptothecin ,Female ,business ,Colorectal Neoplasms ,medicine.drug - Abstract
Purpose We evaluated the safety and efficacy of concurrent administration of two monoclonal antibodies, cetuximab and bevacizumab, in patients with metastatic colorectal cancer. Patients and Methods This was a randomized phase II study in patients with irinotecan-refractory colorectal cancer. All patients were naïve to both bevacizumab and cetuximab. Patients in arm A received irinotecan at the same dose and schedule as last received before study entry, plus cetuximab 400 mg/m2 loading dose, then weekly cetuximab 250 mg/m2, plus bevacizumab 5 mg/kg administered every other week. Patients in arm B received the same cetuximab and bevacizumab as those in arm A but without irinotecan. Results Forty-three patients received cetuximab, bevacizumab, and irinotecan (CBI) and 40 patients received cetuximab and bevacizumab alone (CB). Toxicities were as would have been expected from the single agents. For the CBI arm, time to tumor progression (TTP) was 7.3 months and the response rate was 37%; for the CB arm, TTP was 4.9 months and the response rate was 20%. The overall survival for the CBI arm was 14.5 months and the overall survival for the CB-alone arm was 11.4 months. Conclusion Cetuximab and bevacizumab can be administered concurrently, with a toxicity pattern that seems to be similar to that which would be expected from the two agents alone. This combination plus irinotecan also seems to be feasible. The activity seen with the addition of bevacizumab to cetuximab, or to cetuximab plus irinotecan, seems to be favorable when compared with historical controls of cetuximab or cetuximab/irinotecan in patients who are naïve to bevacizumab.
- Published
- 2007
69. Phase II clinical trial of parenteral hydroxyurea and hyper-fractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: toxicity and efficacy with continuous ribonucleoside reductase inhibition
- Author
-
Richard V. Smith, Carl E. Silver, Madhu Mazumdar, Scott Wadler, Jonathan J. Beitler, and Randall P. Owen
- Subjects
Male ,medicine.medical_specialty ,Radiosensitizer ,medicine.drug_class ,Urology ,Antineoplastic Agents ,Antimetabolite ,Hydroxycarbamide ,Pharmacokinetics ,medicine ,Humans ,Hydroxyurea ,Infusions, Parenteral ,Infusion Pumps ,Aged ,Cisplatin ,Dose-Response Relationship, Drug ,business.industry ,Radiotherapy Dosage ,Middle Aged ,Surgery ,Treatment Outcome ,Otorhinolaryngology ,Epidermoid carcinoma ,Chemotherapy, Adjuvant ,Head and Neck Neoplasms ,Toxicity ,Carcinoma, Squamous Cell ,Female ,Radiotherapy, Adjuvant ,Dose Fractionation, Radiation ,business ,Chemoradiotherapy ,medicine.drug - Abstract
Almost all concurrent chemoradiation regimens for head and neck are platinum based; however, cisplatin is associated with severe renal, oto-, and neurotoxicity. Hydroxyurea (HU) has been associated with fewer irreversible toxicities. We obtained HU in parenteral form to be administered continually during the radiation treatment. Intravenous HU promised better pharmacokinetics and cell cycle blockade.Participants had biopsy-proven, untreated squamous cell carcinoma of the oral cavity, oropharynx (stage IV) and hypopharynx (stages II-IV). Radiation therapy consisted initially of 74.4 Gy administered in twice daily 1.2-Gy fractions. After 20 patients, the radiation dose was reduced to 60.0 Gy, and another 16 patients were enrolled.Patients received HU by Continuous Ambulatory Drug Delivery (CADD) pump on a daily x5 schedule during radiation therapy. Because of persistent long-term dysphagia, after 20 patients, the dose of external beam radiation therapy was reduced from 74 to 60 Gy, and the duration of concurrent HU was correspondingly reduced. The new regimen was much better tolerated. The median survival for the group as a whole was 30 months. Within this small study, there were no significant differences in survival, regional control, or local control between the 2 groups.Lower doses of concurrent parenteral HU and hyper-fractionated radiation therapy are tolerable and promising.
- Published
- 2006
70. A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers
- Author
-
Benny Wong, Manuel Macapinlac, R. Russell Martin, Sanjay Goel, Mark H. Einstein, Kavita K. Desai, Scott Wadler, Gary L. Goldberg, Fabio Volterra, Abbie L. Fields, and Sridhar Mani
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Neutropenia ,Cyclic AMP-Dependent Protein Kinase RIalpha Subunit ,Oligonucleotides ,Breast Neoplasms ,Docetaxel ,Pharmacology ,Drug Administration Schedule ,Transaminase ,Internal medicine ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Pharmacology (medical) ,Protein kinase A ,Infusions, Intravenous ,Aged ,Aged, 80 and over ,Taxane ,Dose-Response Relationship, Drug ,business.industry ,Incidence (epidemiology) ,Middle Aged ,medicine.disease ,Pancreatic Neoplasms ,Antisense oligonucleotides ,Prothrombin Time ,Every Three Weeks ,Female ,Taxoids ,business ,Colorectal Neoplasms ,Febrile neutropenia ,medicine.drug - Abstract
Purpose: GEM®231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1α regulatory subunit of cAMP dependent protein kinase A. Preclinical studies have demonstrated synergistic antitumor activity when GEM®231 is combined with docetaxel. This trial assesses the safety of this combination. Experimental Design: Docetaxel was administered once every three weeks (one-cycle) at doses between 50–75 mg/m2. GEM®231 was administered twice weekly at 220 mg/m2 for 3 (schedule-A), or 2 (schedule-B) weeks. Results: Twenty patients with chemotherapy-refractory advanced cancer received a total of 39 cycles of therapy. Six patients in schedule-A received docetaxel 50 mg/m2, and 14 patients in schedule-B received docetaxel 50–75 mg/m2. In schedule-A, 2 of 6 patients developed cycle-1 dose limiting toxicity (DLT)-grade-3 fatigue or grade-3 serum transaminase elevation. In schedule-B, 1 of 4 patients developed cycle-1 DLT at the highest dose of docetaxel tested (75 mg/m2)—grade–3 febrile neutropenia. Subsequent dose escalations were not pursued since the overall incidence of grade-3 toxicities (including those that occurred after cycle 1) was 75%, and this dose was close to the single agent MTD of docetaxel. Grade-3 toxicities included fatigue (2 patients), transaminase elevation (4 patients), and altered mentation (1 patient). The mean post-infusion aPTT was significantly higher than the pre-infusion value [14.8 seconds; p
- Published
- 2006
71. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma
- Author
-
Scott, Wadler, Howard, Kaufman, Marshall, Horwitz, Stephen, Morley, David, Kirn, Robert, Brown, Stan, Kaye, and David, Soutar
- Subjects
Cancer Research ,Clinical Trials as Topic ,Oncology ,Carcinoma ,Humans ,Antineoplastic Agents ,Mouth Neoplasms ,Viral Vaccines ,Injections, Intralesional ,Immunohistochemistry ,In Situ Hybridization ,Adenoviridae - Published
- 2005
72. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study
- Author
-
Elizabeth R. Plimack, Franco M. Muggia, Robert C. Wallach, Carolyn D. Runowicz, Gary L. Goldberg, John Mandeli, James L. Speyer, Scott Wadler, and Howard S. Hochster
- Subjects
Adult ,medicine.medical_specialty ,Phases of clinical research ,Neutropenia ,Gastroenterology ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Infusions, Intravenous ,Aged ,Cisplatin ,Ovarian Neoplasms ,Taxane ,business.industry ,Obstetrics and Gynecology ,Middle Aged ,medicine.disease ,Surgery ,Oncology ,Toxicity ,Topotecan ,Female ,business ,Ovarian cancer ,Febrile neutropenia ,medicine.drug - Abstract
Objective. To determine the toxicity and efficacy of combined therapy with cisplatin and prolonged infusion topotecan as front line therapy in women with epithelial ovarian cancer. Patients and methods. Women with previously untreated, measurable and non-measurable epithelial ovarian cancer, stages Ic–IV were eligible. Patients were treated with cisplatin 75 mg/m 2 on day 1, followed by topotecan 0.3 to 0.4 mg/m 2 /day given as a continuous infusion over 14–21 days, every 28 days. Dose levels and duration of infusion were adjusted for toxicity as appropriate. Patients were evaluated for response to treatment and treatment toxicity by standard NYGOG criteria. Results. Sixty patients were enrolled. Among the 20 patients with post-surgical residual disease >2 cm, 80% [95% CI (56.3%, 94.3%)] demonstrated an objective response to therapy. The median progression-free survival for all 60 patients enrolled was 19.3 months with a median overall survival of 45.6 months given the median follow-up of 55 months (range 6–81 months). Five year survival is estimated to be 41%. Toxicity was observed in the first four patients treated with topotecan (0.4 mg/m 2 /day × 21 days) and dosing was continued at 0.3 mg/m 2 /day × 14 days thereafter. Of the 56 patients treated at the amended dose level, marrow suppression continued to be dose-limiting, with 86% of patients experiencing grade 3 or 4 neutropenia, 55% experiencing grade 3 or 4 thrombocytopenia and 50% of patients experiencing grade 3 or 4 anemia. Nonetheless, only 11/245 cycles administered were associated with febrile neutropenia and/or infection (8 port-related). Other non-hematologic toxicity was as expected. There were no treatment-related deaths. Conclusion. This large, multicenter phase II study of prolonged infusion topotecan in combination with cisplatin demonstrated similar response, time to progression and survival compared with reported results of taxane and platinum combinations. Hematologic toxicity was greater but tolerated. Further studies investigating topotecan in combination with platinum therapy as a first line agent are warranted.
- Published
- 2005
73. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas
- Author
-
Scott Wadler, John Wright, Robert G. Maki, Jennifer Yamada, Gary K. Schwartz, Cristina R. Antonescu, R N Kelly Scheu, and Andrew S. Kraft
- Subjects
Leiomyosarcoma ,Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Phases of clinical research ,Antineoplastic Agents ,Bone Neoplasms ,Soft Tissue Neoplasms ,Drug Administration Schedule ,Bortezomib ,Internal medicine ,medicine ,Humans ,Neoplasm Metastasis ,Rhabdomyosarcoma ,Fatigue ,Aged ,Chemotherapy ,business.industry ,Soft tissue sarcoma ,Sarcoma ,Middle Aged ,medicine.disease ,Boronic Acids ,Surgery ,Treatment Outcome ,Pyrazines ,Proteasome inhibitor ,Female ,Neoplasm Recurrence, Local ,Nervous System Diseases ,business ,Proteasome Inhibitors ,medicine.drug - Abstract
BACKGROUND: Based on evidence of activity in preclinical and Phase I studies, the authors undertook a study of bortezomib, a reversible proteasome inhibitor, for patients with metastatic sarcomas. METHODS: Two arms were opened, each using a Simon two-stage design. Arm A included patients with osteogenic sarcoma, Ewing sarcoma, and rhabdomyosarcoma. Arm B accrued patients with other types of soft tissue sarcomas. Patients were not allowed to have received previous chemotherapy for metastatic disease. The initial dose of bortezomib was a 1.5 mg/m2 intravenous push twice weekly followed by a rest week. The dose was escalated to 1.7 mg/m2 if patients tolerated Cycle 1 well. The dose escalation was eliminated due to toxicity observed in the first six patients. RESULTS: Painful neuropathy, myalgias, and asthenia were the most significant observed toxicities. The most frequent toxicities included fatigue, diarrhea, constipation, and nausea. Pharmacodynamic data from 18 patients with complete data collection did not show consistent differences between patients with or without Grade 2 or Grade 3 neuropathy (toxicity graded according the National Cancer Institute Common Toxicity Criteria). Arm A had low accrual and was closed. One confirmed partial response among 21 evaluable patients was observed on Arm B in a patient with leiomyosarcoma. Due to the inactivity of this agent, the study was closed after the first stage of accrual. CONCLUSIONS: Bortezomib has minimal activity in soft tissue sarcoma as a single agent. If studied further in sarcomas, bortezomib should be investigated in combination with agents with demonstrated preclinical synergy.
- Published
- 2005
74. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV
- Author
-
Kuniaki Shirao, James L. Abbruzzese, R. G. Wadleigh, I. Hyodo, Peter O'Dwyer, Y. Yamada, Patrick J. Loehrer, N. Boku, Scott Wadler, A. Ohtsu, Fumio Nagashima, Kei Muro, and Paulo M. Hoff
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,medicine.drug_class ,Leucovorin ,Administration, Oral ,Gastroenterology ,Tegafur ,Antimetabolite ,Drug Administration Schedule ,Pharmacokinetics ,Japan ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Uracil ,Aged ,business.industry ,Middle Aged ,medicine.disease ,United States ,Surgery ,Clinical trial ,Diarrhea ,Regimen ,Oncology ,Toxicity ,Female ,medicine.symptom ,business ,Colorectal Neoplasms ,medicine.drug - Abstract
Purpose To compare the efficacy, toxicities, and pharmacokinetics of an oral regimen consisting of uracil/tegafur (UFT) and leucovorin (LV) between Japanese patients and patients in the United States with previously untreated metastatic colorectal cancer. Patients and Methods Forty-four Japanese patients and 45 patients in the United States were enrolled in concurrent nonrandomized phase II trials. UFT 300 mg/m2/d and leucovorin 75 mg/d were administered orally for 28 days followed by a 7-day rest period. The total daily dose of each drug was divided into three equal doses. Treatment was repeated every 5 weeks until disease progression. Blood samples for the pharmacokinetic study were obtained after the initial dose on day 1 of the first course. Results The response rate for the Japanese patients and the patients in the United States was 36.4% (95% CI, 22.4% to 52.2%) and 34.1% (95% CI, 20.5% to 49.9%), respectively. The only major toxicity was diarrhea, and other toxicities were mild in both populations. The incidence of grade 3 or higher diarrhea in the Japanese and Americans was 9% and 22%, respectively. Although the area under the curve and maximum concentration of fluorouracil were found to be slightly higher in the Japanese patients than the patients in the United States, and area under the curve–adjusted body surface area appeared to be comparable between the two groups. Conclusion The efficacy and pharmacokinetic parameters of UFT and LV are comparable in Japanese and American patients; however, a difference in toxicity profile, specifically diarrhea, was noted. This oral regimen of UFT and LV is considered to have similar activity against metastatic colorectal cancer and to have acceptable toxicity in patients in both countries.
- Published
- 2004
75. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma
- Author
-
Camillo Porta, Mauro Moroni, Giuseppe Nastasi, Enrico Bobbio-Pallavicini, Giancarlo Barazzoni, Scott Wadler, Curtis W. Bakal, Jacob Cynamon, and Peter H. Wiernik
- Subjects
Cancer Research ,Oncology - Published
- 1995
76. Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors
- Author
-
Franco M. Muggia, Percy Ivy, E. Harvey, Merrill J. Egorin, G. Lockwood, William C. Zamboni, G. Renshaw, L. Leibes, Sanjay Goel, Sridhar Mani, A. Bulgaru, Howard S. Hochster, and Scott Wadler
- Subjects
Adult ,Male ,medicine.medical_specialty ,Organoplatinum Compounds ,medicine.medical_treatment ,Neutropenia ,Gastroenterology ,Deoxycytidine ,Drug Administration Schedule ,Internal medicine ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged ,Chemotherapy ,Dose-Response Relationship, Drug ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Gemcitabine ,Surgery ,Oxaliplatin ,Clinical trial ,Regimen ,Treatment Outcome ,Oncology ,Fluorouracil ,Toxicity ,Female ,business ,medicine.drug - Abstract
The aim of this study was to determine the maximum tolerated dose, recommended phase II dose (RPTD) and toxicities of the FOG regimen (infusional 5-fluorouracil, oxaliplatin, gemcitabine).Patients with advanced solid tumors were treated in an accelerated titration scheme. 5-Fluorouracil was administered intravenously at 200 mg/m(2)/day for 14 days and repeated every 21 days (one cycle). Gemcitabine was administered on days 1 and 8 over 30 min at 450-650 mg/m(2). Oxaliplatin was administered on day 1 over 2 h at 85-130 mg/m(2). For cycles 1, 3 and beyond, gemcitabine followed oxaliplatin; for cycle 2, gemcitabine preceded oxaliplatin.Forty-five and 39 patients were assessable for toxicity and response, respectively. Cycle 1 dose-limiting toxicities (DLT) included neutropenia, thrombocytopenia and diarrhea. No DLT was observed in cycle 1 at the first four dose levels (DL). At DL-5, two of four (50%) patients experienced DLT in cycle 1. Expanding DL-4, nine of 26 (35%) patients experienced DLT in cycle 1. Because recurrent grade 3 toxicities were observed in three of six (50%) patients at DL-3, DL-2 was considered the RPTD. At the RPTD, three patients had a partial response (response rate 23%).The RPTD for the 5-fluorouracil-oxaliplatin-gemcitabine combination is 200/100/450 mg/m(2). This novel regimen has demonstrated activity in advanced solid tumors and merits further investigation.
- Published
- 2003
77. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96
- Author
-
Scott, Wadler, Donna, Levy, Helen L, Frederickson, Carla I, Falkson, Yuexian, Wang, Edie, Weller, Robert, Burk, Gloria, Ho, and Anna S, Kadish
- Subjects
Adult ,Repressor Proteins ,Immunity, Cellular ,Treatment Outcome ,Papillomavirus E7 Proteins ,Humans ,Uterine Cervical Neoplasms ,Female ,Oncogene Proteins, Viral ,Middle Aged ,Interleukin-12 ,Aged - Abstract
The ability to mount lymphoproliferative responses to peptides derived from the human papillomavirus (HPV) E6 and E7 oncoproteins has been associated with regression of dysplastic lesions of the uterine cervix and loss of associated HPV infection. Interleukin-12 (IL-12) is a potent immunopotentiator of T-cell function, and has been shown in phase I clinical trials to be tolerable.Patients were required to have measurable metastatic, recurrent or inoperable cervical carcinoma. Patients could have had one prior adjuvant regimen and one prior regimen for advanced disease. Treatment consisted of IL-12 administered at 250 ng/kg IV as a rapid push in the outpatient setting daily x 5 every 21 days. Whole blood samples were acquired twice before treatment then approximately every 3 weeks to assess lymphoproliferative response in vitro to HPV type 16 (HPV 16) E4, E6, and E7 peptides. These responses were correlated with demographics and with clinical outcome.Thirty-four patients were enrolled; 29 were evaluable. Over half had received cisplatin-based chemotherapy. The most common serious toxicities were hematologic or hepatic, and all were reversible. There was one partial responder (3%). The median survival was 6.5 months (95% CI: 5.8, 11.5 months). Eighteen of 29 eligible patients had evaluable laboratory data both pre- and post-therapy. There was a statistically significant increase in lymphoproliferative responses for HPV 16 E4, E6, and E7 peptides (P=0.020, 0.020, 0.043). There was a significant association between change in lymphoproliferative response to HPV 16 E6 peptides and number of cycles of treatment administered (P=0.048). There was no correlation between change in lymphoproliferative response to any peptide with age, performance status, race, prior chemotherapy, time from diagnosis to treatment, or with overall survival.IL-12 treatment was associated with improved lymphoproliferative responses to HPV 16 E4, E6, and E7 peptides. This is the first clinical trial to demonstrate induction of cell-mediated immune (CMI) responses to specific antigens (peptides) following treatment with IL-12 in women with cervical cancer. This improvement in immune response was not associated with enhanced objective response or survival.
- Published
- 2003
78. Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors
- Author
-
Ron Kaleya, Andreas Kaubisch, Scott Wadler, H. Haynes, and Alla M. Rozenblit
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Filgrastim ,medicine.drug_class ,Injections, Subcutaneous ,Pharmacology ,Toxicology ,Antimetabolite ,Thymidylate synthase ,Drug Administration Schedule ,Hydroxycarbamide ,Oral administration ,Stomach Neoplasms ,Internal medicine ,Pancreatic cancer ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,medicine ,Humans ,Hydroxyurea ,Pharmacology (medical) ,Neoplasm Metastasis ,Infusions, Intravenous ,Aged ,biology ,business.industry ,Middle Aged ,medicine.disease ,Recombinant Proteins ,Granulocyte colony-stimulating factor ,Pancreatic Neoplasms ,Neuroendocrine Tumors ,Endocrinology ,Treatment Outcome ,Oncology ,Fluorouracil ,biology.protein ,Female ,Interferons ,business ,medicine.drug - Abstract
Combined inhibition of ribonucleotide reductase (RR) and thymidylate synthase (TS), the enzymes responsible for a balanced supply of nucleotides for DNA synthesis, has been shown to induce synergistic antiproliferative effects in vitro. In the clinic, prolonged infusion of the RR inhibitor, hydroxyurea (HU), may be more effective than bolus or oral administration of drug. The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies.A clinical trial of parenteral, weekly, high-dose HU in combination with weekly, high-dose infusional fluorouracil (5FU) was initiated in patients with advanced pancreatic and gastric cancer. Patients received 5FU 1.3 g/m(2) by continuous intravenous infusion (CIVI) daily over 48 h weekly in combination with HU 4.3 g/m(2) CIVI per day over 48 h weekly. Patients also received the biologic agent interferon alfa-2a 9 MU subcutaneously (s.c.) three times per week and filgrastim 480 microg s.c. on days 3 (starting after midday), 4, 5, and 6 each week. Each cycle required treatment on days 1 and 8 every 22 days.Enrolled in the study were 32 patients, of whom 30 were evaluable. The median age was 56 years. Primary sites included pancreas (18), gastric (13) and islet cell (1). Despite filgrastim, the major toxicities were hematologic with 15 of 30 patients developing grade 3/4 granulocytopenia. Of the 30 patients, 4 developed grade 3/4 diarrhea. Interferon-mediated fatigue was mild. Of 12 evaluable patients with gastric cancer, 1 had a partial response, and there were no responders among patients with pancreatic cancer.Combined inhibition of RR and TS using this high-dose, weekly, 48-h infusional regimen is not an improvement over single-agent therapy in these tumor types.
- Published
- 2003
79. Clinical applications of p53-directed gene therapy
- Author
-
Della Makower, Jian You Tan, Morris Edelman, James Zwiebel, Howard Kaufman, Alla M. Rozenblit, Bo Yu, Maureen E. Lane, and Scott Wadler
- Subjects
Cancer Research ,Clinical Trials as Topic ,business.industry ,Viral Vaccine ,Genetic enhancement ,Liver Neoplasms ,Viral Vaccines ,General Medicine ,Computational biology ,Genetic Therapy ,Injections, Intralesional ,medicine.disease_cause ,Genes, p53 ,Prognosis ,Genetic therapy ,Adenoviridae ,Gene Expression Regulation, Neoplastic ,Text mining ,Oncology ,Medicine ,Humans ,business - Published
- 2003
80. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies
- Author
-
Della, Makower, Alla, Rozenblit, Howard, Kaufman, Morris, Edelman, Maureen E, Lane, James, Zwiebel, Hilda, Haynes, and Scott, Wadler
- Subjects
Adult ,Male ,Liver Neoplasms ,Viral Vaccines ,Viral Plaque Assay ,Injections, Intralesional ,Middle Aged ,Antibodies, Viral ,Genes, p53 ,Adenoviridae ,Treatment Outcome ,Bile Duct Neoplasms ,Mutation ,Humans ,Female ,Gallbladder Neoplasms ,Neoplasm Metastasis ,Aged - Abstract
ONYX-015 is a genetically modified adenovirus with a deletion of the E1B early gene and is therefore designed to replicate preferentially in p53-mutated cells. A Phase II trial of intralesional ONYX-015 was conducted in patients with hepatobiliary tumors to determine the safety and efficacy of such a treatment.All patients had biopsy-proven, measurable tumors of the liver, gall bladder, or bile ducts that were beyond the scope of surgical resection. Patients received intralesional injections of ONYX-015 at either 6 x 10(9) or 1 x 10(10) plaque-forming units/lesion up to a total dose of 3 x 10(10) plaque-forming units, and i.p. injections were allowed in patients with malignant ascites. The status of p53 was assessed by immunohistochemistry or Affymetrix GeneChip microarray analysis. Studies were conducted for viral shedding and for the presence of antiadenoviral antibodies before and after the injection of ONYX-015. Patients were assessed for response and toxicity.Twenty patients were enrolled, and 19 patients were eligible. Half of the patients had primary bile duct carcinomas. Serious toxicities (grade 2) were uncommon and included hepatic toxicity (three patients), anemia (one patient), infection (one patient), and cardiac toxicity (one patient, atrial fibrillation). Sixteen patients were evaluable for response. Among these evaluable patients, 1 of 16 (6.3%) had a partial response, 1 of 16 (6.3%) had prolonged disease stabilization (49 weeks), and 8 of 16 (50%) had a50% reduction in tumor markers. Of the 19 eligible patients, 18 (94.7%) had specimens available for p53 analysis. Fifteen of these 18 patients (83.3%) had evidence of p53 mutation by one or both methods, although the methods correlated poorly. Viral shedding was confined to bile (two of two patients) and ascites (four of four patients). Pretreatment adenoviral antibodies were present in 14 of 14 patients and increased by 33.2% after ONYX-015 treatment.Intralesional treatment with ONYX-015 in patients with hepatobiliary tumors is safe and well tolerated, and some patients had evidence of an anticancer effect. The high incidence of p53 mutations in these tumors makes this a logical population in which to test this therapy but precludes definitive evaluation about the necessity of a p53 mutation for ONYX-015 clinical activity.
- Published
- 2003
81. Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants
- Author
-
Scott, Wadler, Bo, Yu, Jian-You, Tan, Ron, Kaleya, Alla, Rozenblit, Della, Makower, Morris, Edelman, Maureen, Lane, Elizabath, Hyjek, and Marshall, Horwitz
- Subjects
Clinical Trials as Topic ,Cytoplasm ,Time Factors ,Reverse Transcriptase Polymerase Chain Reaction ,Carcinoma ,Viral Vaccines ,Middle Aged ,Genes, p53 ,Adenoviridae ,Blotting, Southern ,Necrosis ,Tumor Cells, Cultured ,Humans ,Female ,Gallbladder Neoplasms ,Stromal Cells ,Tumor Suppressor Protein p53 ,In Situ Hybridization ,DNA Primers ,Oligonucleotide Array Sequence Analysis - Abstract
ONYX-015 is a chimeric, E1B-deleted adenovirus designed to replicate preferentially in p53-deficient tumor cells; however, little is understood about its actual replication potential in human tumors. We hypothesized that replication of a late viral gene, hexon, would demonstrate replication of virus in human tissues.In the course of a clinical trial, a patient with paired abdominal wall implants from a primary gall bladder carcinoma was injected with ONYX-015, 1 x 10(10) viral particles/lesion, followed by sequential excision of the lesions at 37 h and 7 days. Tissue sections were analyzed for evidence of viral replication.In situ Reverse transcription-PCR was used to measure expression of hexon. Strong signals were obtained in gland-forming tumor cells both at 37 h and at 7 days. Signal was predominantly observed in the cytoplasm. The signal was also observed in adjacent normal stromal cells. Analysis of p53 status of the tumor by immunohistochemistry and Affymetrix Genechip demonstrated an inactivating mutation in p53. Routine HE staining of the tumor sections revealed no evidence of necrosis at 37 h or 7 days after injection of virus. Presence of viral protein at both 37 h and 7 days was confirmed by immunohistochemistry using antibodies directed against hexon, penton, and fiber proteins.Evidence for replication of hexon confirms that ONYX-015 is not only present but capable of replicating in tumor cells up to 1 week after intralesional injection and that replication is not confined to p53-mutated tumor cells.
- Published
- 2003
82. Advances in the treatment of metastatic colorectal cancer
- Author
-
Ari D. Fishman and Scott Wadler
- Subjects
Oncology ,medicine.medical_specialty ,Organoplatinum Compounds ,Colorectal cancer ,medicine.medical_treatment ,Administration, Oral ,Antineoplastic Agents ,Thiophenes ,Irinotecan ,Cancer Vaccines ,Deoxycytidine ,Drug Administration Schedule ,law.invention ,Capecitabine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Prodrugs ,Neoplasm Metastasis ,Uracil ,Randomized Controlled Trials as Topic ,Chemotherapy ,business.industry ,Liver Neoplasms ,Gastroenterology ,Antibodies, Monoclonal ,medicine.disease ,Oxaliplatin ,Regimen ,Quinazolines ,Camptothecin ,Fluorouracil ,business ,Colorectal Neoplasms ,Raltitrexed ,medicine.drug - Abstract
Colorectal cancer represents the third leading cause of cancer mortality in the United States. During the past four decades, 5-fluorouracil (5-FU) has served as the cornerstone of therapy for individuals with advanced colorectal cancer (ACRC). Despite numerous attempts at maximizing efficacy of 5-FU through biochemical modulation, a significant benefit in terms of survival has never been realized. The recent emergence of novel chemotherapeutic drugs employing different mechanisms of action than 5-FU has led to the incorporation of irinotecan (CPT-11) with 5-FU/leucovorin as the new standard first-line regimen for future trials. This review outlines emerging data utilizing oral fluoropyrimidines and other new agents including oxaliplatin, raltitrexed, and eniluracil. Randomized clinical trials are currently underway in an effort to define optimal combination chemotherapy regimens, scheduling of agents, duration of therapy, and choice of therapy using a variety of prognostic molecular markers.
- Published
- 2002
83. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies
- Author
-
Minaxi Jhawer, Leon Landau, Anthony Hoffman, Hoo G. Chun, Cheryl Baker, Lakshmi Rajdev, Una Hopkins, Sanjay Goel, Sridhar Mani, Scott Wadler, Della Makower, and Karen Fehn
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Maximum Tolerated Dose ,Colorectal cancer ,medicine.medical_treatment ,Phases of clinical research ,Administration, Oral ,Neutropenia ,Irinotecan ,Gastroenterology ,Deoxycytidine ,Capecitabine ,Oral administration ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Infusions, Intravenous ,Aged ,Gastrointestinal Neoplasms ,Aged, 80 and over ,Chemotherapy ,business.industry ,Middle Aged ,medicine.disease ,Surgery ,Regimen ,Oncology ,Camptothecin ,Female ,Fluorouracil ,business ,medicine.drug - Abstract
The purpose of this study was to determine the safety of irinotecan and capecitabine in patients with advanced solid tumors. Thirty-four patients received 122 courses of irinotecan 200 to 300 mg/m 2 as an intravenous infusion during 30 minutes on day 1 and capecitabine 1,500 to 3,000 mg/d orally 12 hours apart starting on day 2 for 14 days, repeated every 21 days (one course). Three to seven patients were treated in six dose-escalation cohorts. Three of 7 (43%) patients treated with irinotecan 300 mg/m 2 and capecitabine 2,300 mg/d had course 1 dose-limiting toxicity (DLT) defining maximum tolerated dosage (MTD). Fatigue and diarrhea were the major DLTs, and other events included neutropenia, anorexia, and hand-foot syndrome. At one dose level below the MTD, none of 7 patients treated with irinotecan 275 mg/m 2 , and capecitabine 2,300 mg/d (36 courses) had course 1 DLT. Grade III to IV toxicities beyond course 1 included neutropenia (11% of all courses), fatigue (3.4%) and hand-foot syndrome (3.4%). There were only two episodes of febrile grade II neutropenia. There were no toxic deaths. Transient antitumor response was noted in one patient with irinotecan and 5-fluorouracil-refractory colon cancer. The combination of irinotecan 275 mg/m 2 and capecitabine 2,300 mg/d represents a safe, favorable, and convenient outpatient regimen warranting further phase II evaluation.
- Published
- 2002
84. Radiofrequency ablation of head and neck tumors: dramatic results from application of a new technology
- Author
-
Jacqueline A. Bello, Jonathan J. Beitler, Thanjavur S. Ravikumar, Scott Wadler, Randall P. Owen, and Carl E. Silver
- Subjects
Male ,medicine.medical_specialty ,Radiofrequency ablation ,medicine.medical_treatment ,Cutaneous Fistula ,law.invention ,Catheterization ,Postoperative Complications ,law ,Sepsis ,Medicine ,Humans ,Aged ,Chemotherapy ,business.industry ,Cancer ,Perioperative ,Pneumonia ,Middle Aged ,Ablation ,medicine.disease ,Surgery ,Tongue Neoplasms ,Radiation therapy ,Otorhinolaryngology ,Epidermoid carcinoma ,Carcinoma, Squamous Cell ,Catheter Ablation ,Female ,Neoplasm Recurrence, Local ,business ,Complication ,Mouth Diseases - Abstract
Background Radiofrequency ablation (RFA) is a new treatment modality used over the past decade predominantly in the treatment of unresectable liver tumors. We find no prior reported series on the use of RFA for malignant tumors of the head and neck. Methods Four patients with recurrent tongue tumors not amenable to standard surgical or radiation therapy were treated with RFA administered transorally, endoscopically, or percutaneously. Results There was no perioperative mortality. Significant palliation was achieved consisting of substantial reduction in tumor size and alleviation of tumor-induced pain. One patient has survived for 8 months with no progression of tumor. Three patients had complications, including line sepsis, pneumonia, and enlargement of an orocutaneous fistula. Conclusions RFA was relatively straightforward to apply, achieved substantial palliation, and was associated with minimal perioperative morbidity and no mortality. It might easily be combined with other therapies such as chemotherapy, immunotherapy, or radiation. Further investigation is necessary and ongoing. © 2002 Wiley Periodicals, Inc. Head Neck 24: 754–758, 2002
- Published
- 2002
85. Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296
- Author
-
Scott, Wadler, Carlos, Brain, Paul, Catalano, Avi I, Einzig, David, Cella, and Al B, Benson
- Subjects
Adult ,Male ,Filgrastim ,Paclitaxel ,Interferon-alpha ,Docetaxel ,Interferon alpha-2 ,Middle Aged ,Recombinant Proteins ,Treatment Outcome ,Doxorubicin ,Stomach Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,Quality of Life ,Humans ,Hydroxyurea ,Female ,Taxoids ,Fluorouracil ,Fatigue ,Aged - Abstract
The Eastern Cooperative Oncology Group conducted a randomized phase II trial to determine the objective response rates, toxicities, and overall survival and to assess effects on quality of life for two combination regimens in patients with advanced gastric cancer.All patients had biopsy-proven, untreated metastatic gastric cancer with measurable disease. The FHIG arm employed infusional fluorouracil (F), 2.6 g/m2, given intravenously over 24 hours once perweek for 6 weeks; infusional hydroxyurea (H), 4.3 g/m2, given intravenously over 24 hours once per week for 6 weeks; and interferon-alpha-2a (1), 9 MU given subcutaneously three times per week, once per week for 6 weeks. The AD arm employed doxorubicin (A), 50 mg/m2, and docetaxel (D), 75 mg/m2, both given intravenously every 21 days. Quality of life was measured by the FACT-Fatigue scale and a novel questionnaire assessing interferon-mediated fatigue.Twenty-nine patients were enrolled; 23 were eligible and evaluable. Twelve were enrolled on FHIG and 11 on AD. The major gradeor = 3 toxicities were neuromotor (46%) in patients receiving FHIG and granulocytopenia (91%) in those receiving AD. There were two fatalities in the AD arm. There was one partial responder on FHIG (8.3%) and none on AD. The median survival was 6.6 months for FHIG and 10.1 months for AD. Quality-of-life analysis did not show substantial cumulative fatigue in patients treated with FHIG.Neither regimen demonstrated enough activity to serve as a platform for the development of further clinical regimens against gastric carcinoma. A subset of patients receiving interferon was able to tolerate therapy without deterioration in quality of life.
- Published
- 2002
86. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96
- Author
-
Donna E. Levy, Peter Beatty, Scott Wadler, Francine M. Foss, Howard H. Bailey, Julian C. Schink, and Linda Harris
- Subjects
Oncology ,medicine.medical_specialty ,Nausea ,medicine.medical_treatment ,Phases of clinical research ,Antineoplastic Agents ,Disease-Free Survival ,Drug Administration Schedule ,chemistry.chemical_compound ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,Triglycerides ,Aged ,Ovarian Neoplasms ,Chemotherapy ,Cholesterol ,business.industry ,Terpenes ,Perillyl alcohol ,Cholesterol, HDL ,Obstetrics and Gynecology ,Cholesterol, LDL ,Middle Aged ,Clinical trial ,chemistry ,Toxicity ,Monoterpenes ,Patient Compliance ,Female ,medicine.symptom ,business - Abstract
Objective. This was a phase II study of perillyl alcohol in the treatment of advanced ovarian cancer. The primary endpoint was to evaluate the 6-month progression-free rate of perillyl alcohol as compared with historic controls. Secondary objectives were to evaluate the objective response rate, time to progression and survival, dropout rate, and number of cycles administered; define the qualitative nature of acute and chronic toxicities; and evaluate the effect of perillyl alcohol on triglycerides and total, HDL, and LDL cholesterol levels. Methods. Women who had received prior platinum-based therapy and had residual or recurrent disease were eligible. Perillyl alcohol was administered orally, four times daily, at a dose of 1200 mg/m 2 . This was repeated until disease progression or unacceptable toxicity was experienced. Results. The 6-month progression-free rate was 17%. None of the patients achieved a complete or partial response. The median progression-free survival was 1.7 months. The median overall survival was 9.1 months. Compliance was greater than 90% but gastrointestinal toxicity (grade 1–2 nausea, satiety, eructation in 70%) and fatigue (grade 1–2 in 40%) were common and limited the ability to escalate the dose from 1200 to 1500 mg/m 2 . Conclusion. Perillyl alcohol administered at this dose and formulation did not exhibit signs of extending the time-to-progression in patients with advanced ovarian carcinoma.
- Published
- 2002
87. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin
- Author
-
Scott Wadler, N. J. Meropol, Eric Van Cutsem, Elizabeth A. Poplin, Mace L. Rothenberg, Harry Bleiberg, and Angelo Di Leo
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Leucovorin ,Thrombosis ,Syndrome ,Irinotecan ,Gastroenterology ,Bolus (medicine) ,Oncology ,Fluorouracil ,Cardiovascular Diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Camptothecin ,business ,Colorectal Neoplasms ,medicine.drug - Published
- 2002
88. New developments in the treatment of ovarian cancer
- Author
-
Scott Wadler
- Subjects
Oncology ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,Antineoplastic Agents ,Disease ,chemistry.chemical_compound ,Internal medicine ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Pharmacology ,Ovarian Neoplasms ,Salvage Therapy ,Chemotherapy ,Clinical Trials as Topic ,business.industry ,General Medicine ,Genetic Therapy ,medicine.disease ,Carboplatin ,Clinical research ,chemistry ,Topotecan ,Female ,Cisplatin ,Ovarian cancer ,business ,Camptothecin ,medicine.drug - Abstract
Ovarian cancer accounts for about 4% of all cancers in women in the United States, with over 23,000 cases diagnosed annually. Since patients often present with non-specific symptoms, diagnosis is generally made when disease has spread to the peritoneal cavity. Multi-modality therapy is established as the standard approach to treatment. Surgery remains a cornerstone of therapy for diagnosis, staging and treatment. Almost all patients receive some form of chemotherapy, either in the adjuvant setting or for locally advanced or advanced disease. The treatment of ovarian cancer has rapidly evolved in the past decade. Starting with the initial observation that alkylating agents were active in the treatment of this disease, new classes of agents have been rapidly incorporated in the therapeutic armamentarium. This has included the platinum compounds, taxanes and most recently, camptothecin derivatives, inhibitors of topoisomerase I. Much of the recent clinical research has revolved around how to incorporate these agents with surgery.
- Published
- 2002
89. Histone acetylation and the cell-cycle in cancer
- Author
-
Maofu Fu, Sridhar Mani, Scott Wadler, A M Senderowicz, Chenguang Wang, and Richard G. Pestell
- Subjects
Saccharomyces cerevisiae Proteins ,Antineoplastic Agents ,Apoptosis ,SAP30 ,Histone Deacetylases ,Histones ,Acetyltransferases ,Neoplasms ,Histone H2A ,Histone methylation ,Animals ,Humans ,Histone Acetyltransferases ,Histone deacetylase 5 ,Chemistry ,Histone deacetylase 2 ,Cell Cycle ,Acetylation ,HDAC4 ,Chromatin ,Cyclin-Dependent Kinases ,Cell biology ,Histone Deacetylase Inhibitors ,Histone methyltransferase ,Histone deacetylase ,DNA Damage - Abstract
A number of distinct surveillance systems are found in mammalian cells that have the capacity to interrupt normal cell-cycle progression. These are referred to as cell cycle check points. Surveillance systems activated by DNA damage act at three stages, one at the G1/S phase boundary, one that monitors progression through S phase and one at the G2/M boundary. The initiation of DNA synthesis and irrevocable progression through G1 phase represents an additional checkpoint when the cell commits to DNA synthesis. Transition through the cell cycle is regulated by a family of protein kinase holoenzymes, the cyclin-dependent kinases (Cdks), and their heterodimeric cyclin partner. Orderly progression through the cell-cycle checkpoints involves coordinated activation of the Cdks that, in the presence of an associated Cdk-activating kinase (CAK), phosphorylate target substrates including members of the "pocket protein" family. One of these, the product of the retinoblastoma susceptibility gene (the pRB protein), is phosphorylated sequentially by both cyclin D/Cdk4 complexes and cyclin E/Cdk2 kinases. Recent studies have identified important cross talk between the cell-cycle regulatory apparatus and proteins regulating histone acetylation. pRB binds both E2F proteins and histone deacetylase (HDAC) complexes. HDAC plays an important role in pRB tumor suppression function and transcriptional repression. Histones are required for accurate assembly of chromatin and the induction of histone gene expression is tightly coordinated. Recent studies have identified an important alternate substrate of cyclin E/Cdk2, NPAT (nuclear protein mapped to the ATM locus) which plays a critical role in promoting cell-cycle progression in the absence of pRB, and contributes to cell-cycle regulated histone gene expression. The acetylation of histones by a number of histone acetyl transferases (HATs) also plays an important role in coordinating gene expression and cell-cycle progression. Components of the cell-cycle regulatory apparatus are both regulated by HATs and bind directly to HATs. Finally transcription factors have been identified as substrate for HATs. Mutations of these transcription factors at their sites of acetylation has been associated with constitutive activity and enhanced cellular proliferation, suggesting an important role for acetylation in transcriptional repression as well as activation. Together these studies provide a working model in which the cell-cycle regulatory kinases phosphorylate and inactivate HDACs, coordinate histone gene expression and bind to histone acetylases themselves. The recent evidence for cross-talk between the cyclin-dependent kinases and histone gene expression on the one hand and cyclin-dependent regulation of histone acetylases on the other, suggests chemotherapeutics targeting histone acetylation may have complex and possibly complementary effects with agents targeting Cdks.
- Published
- 2001
90. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
- Author
-
Brian N. Bundy, Maurie Markman, Joshua Sickel, Scott Wadler, Daniel L. Clark-Pearson, Linda F. Carson, Jeffrey M. Fowler, and David S. Alberts
- Subjects
Cancer Research ,medicine.medical_specialty ,Neoplasm, Residual ,Paclitaxel ,medicine.medical_treatment ,Urology ,Gynecologic oncology ,Neutropenia ,Disease-Free Survival ,Drug Administration Schedule ,Carboplatin ,chemistry.chemical_compound ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged ,Cisplatin ,Ovarian Neoplasms ,Chemotherapy ,business.industry ,Middle Aged ,medicine.disease ,Surgery ,Regimen ,Oncology ,chemistry ,Injections, Intravenous ,Female ,Ovarian cancer ,business ,Injections, Intraperitoneal ,medicine.drug - Abstract
PURPOSE: To compare the progression-free and overall survival in small-volume residual ovarian cancer after treatment with intravenous (IV) cisplatin and paclitaxel or an experimental regimen of IV carboplatin followed by IV paclitaxel and intraperitoneal cisplatin. PATIENTS AND METHODS: Patients were randomized to receive either IV paclitaxel 135 mg/m2 over 24 hours followed by IV cisplatin 75 mg/m2 every 3 weeks for six courses or IV carboplatin (area under curve 9) every 28 days for two courses, then IV paclitaxel 135 mg/m2 over 24 hours followed by intraperitoneal (IP) cisplatin 100 mg/m2 every 3 weeks for six courses. RESULTS: Of the 523 patients who entered this trial, 462 were determined to be assessable, with prognostic factors well balanced between the treatments. Neutropenia, thrombocytopenia, and gastrointestinal and metabolic toxicities were greater in the experimental arm. As a result, 18% of the patients received ≤ two courses of IP therapy. Progression-free survival was superior for patients randomized to the experimental treatment arm (median, 28 v 22 months; relative risk, 0.78; log-rank P = .01, one-tail). There was a borderline improvement in overall survival associated with this regimen (median, 63 v 52 months; relative risk, 0.81; P = .05, one-tail). CONCLUSION: An experimental regimen including moderately high-dose IV carboplatin followed by IP paclitaxel and IV cisplatin yielded a significant improvement in progression-free survival when compared with a standard regimen of IV cisplatin and paclitaxel. Because the improvement in overall survival was of borderline statistical significance and toxicity was greater, the experimental arm is not recommended for routine use. However, the results provide direction for further clinical investigation in small-volume ovarian cancer.
- Published
- 2001
91. Gynecologic Malignancies
- Author
-
Scott Wadler
- Published
- 2001
92. Antisense therapeutics in oncology: points to consider in their clinical evaluation
- Author
-
Yun Gu, Scott Wadler, Howard Fingert, and Sridhar Mani
- Subjects
Pharmacology ,Antisense therapy ,Oncology ,medicine.medical_specialty ,Clinical Trials as Topic ,business.industry ,government.form_of_government ,Cytostatic agents ,Rational design ,Gene Expression ,Tumor cells ,Apoptosis ,Oligonucleotides, Antisense ,Internal medicine ,Neoplasms ,Genetics ,government ,Medicine ,Humans ,business ,Clinical evaluation ,Toxicity profile - Abstract
Novel therapeutics in oncology stem from a rational design of drugs targeting selective pathways that stimulate and maintain tumor cell growth. Many of these agents are cytostatic in action and also have a limited toxicity profile. However, some can be cytotoxic if they successfully modulate molecular pathways of apoptosis, such as bcl-2. This article discusses points to consider in the design of one class of cytostatic agents, antisense therapy. Our purpose is to stimulate designs that answer the question specifically with regard to proof-of-concept, and the concepts proposed should be viewed as ideas in development rather than firm recommendations.
- Published
- 2000
93. Carcinoma of the uterine cervix metastatic to behind the zygomatic arch: a case report
- Author
-
Scott Wadler, Robin J. Mitnick, Richard V. Smith, Dwayne Breining, and Jagathi D. Challagalla
- Subjects
Adult ,medicine.medical_specialty ,Zygoma ,business.industry ,medicine.medical_treatment ,Cancer ,Uterine Cervical Neoplasms ,Soft Tissue Neoplasms ,medicine.disease ,Malignancy ,Primary tumor ,Surgery ,Metastasis ,Radiation therapy ,medicine.anatomical_structure ,Otorhinolaryngology ,Carcinoma ,medicine ,Carcinoma, Squamous Cell ,Pelvic tumor ,Humans ,Zygomatic arch ,Female ,business - Abstract
Purpose: We propose to present a novel case of a genital malignancy metastatic to the head and neck. Carcinoma of the uterine cervix is the third most frequent malignancy of the female genital tract. Early detection and improved radiation and surgical techniques have resulted in better control of the pelvic tumor and a greater incidence of distant metastasis. Metastases to the soft tissue of the head and neck region have not been reported. Methods: We present the first known case of a 35-year-old woman with cancer of the uterine cervix who presented with metastasis to the soft tissue behind the zygomatic arch. Results: The patient received radiation therapy to the zygomatic region and cisplatin therapy with a near-complete remission. Conclusion: This case shows that not all squamous cell cancers detected above the clavicles are from a thoracic or a head and neck primary tumor. The atypical location should alert the physician to suspect distant metastasis, rather than locoregional disease.
- Published
- 1999
94. Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells
- Author
-
Scott Wadler, Hong Yang Zhang, Robert Horowitz, and Edward L. Schwartz
- Subjects
Transcription, Genetic ,Macromolecular Substances ,Deoxyribonucleotides ,Reductase ,Biology ,Interferon alpha-2 ,Biochemistry ,S Phase ,chemistry.chemical_compound ,Ribonucleotide Reductases ,Tumor Cells, Cultured ,Humans ,Hydroxyurea ,RNA, Messenger ,Pharmacology ,Cell Cycle ,G1 Phase ,Interferon-alpha ,G1/S transition ,Cell cycle ,Genes, p53 ,Deoxyuridine ,Recombinant Proteins ,Deoxyribonucleoside ,Gene Expression Regulation, Neoplastic ,Ribonucleotide reductase ,chemistry ,Cell culture ,Pyrimidine metabolism ,Colonic Neoplasms ,Mutation ,Fluorouracil ,Cell Division - Abstract
Effects of drug treatment with antimetabolites on a human colon cancer cell line, SW480, were studied. Cells were treated with 10 microM of 5-fluorouracil (5FU), an inhibitor of pyrimidine synthesis, or 1000 microM of hydroxyurea (HU), an inhibitor of both purine and pyrimidine syntheses, or the combination. Recombinant alpha-2a-interferon (IFN), 500 U/mL, also was employed, as this augments the effects of both antimetabolites in vitro and in vivo. The predominant effect of this combination was to block cells in early S phase as measured by 5-bromo-2'-deoxyuridine (BrdUrd) incorporation. By 24 hr, 86% of the cells had accumulated in S phase, but failed to progress to G2/M. This was accompanied by an early, rapid decline in all four deoxyribonucleoside triphosphates (dNTPs) by 38-86% at 4-24 hr. Despite these effects, expression of the G1/S transition state enzyme, ribonucleotide reductase (RR), increased at 24 hr as measured by a 3 to 5-fold increase in mRNA levels for the M2 subunit, in the absence of a measurable effect on protein levels. The rise in levels of RR mRNA and the continued progression of cells into S phase were associated with a synergistic inhibition of cell cycle proliferation resulting from treatment with the three-drug combination. This suggests that in the presence of antimetabolite-induced depletion of dNTPs, SW480 cells, which lack a normal p53 gene, will proceed into S phase, and that this is associated with a rise in expression of the G1/S transition state enzyme, RR. Cells arrested in S phase by a p53-independent mechanism will undergo a synergistic enhancement of cell death.
- Published
- 1999
95. Quantification of ribonucleotide reductase expression in wild-type and hydroxyurea-resistant cell lines employing in situ reverse transcriptase polymerase chain reaction and a computerized image analysis system
- Author
-
Hongyang Zhang, Michael Cammer, Scott Wadler, and Xiou-Ping Hu
- Subjects
Biophysics ,Drug Resistance ,Biology ,Biochemistry ,Gene Expression Regulation, Enzymologic ,Cell Line ,Gene expression ,Ribonucleotide Reductases ,Image Processing, Computer-Assisted ,Humans ,Hydroxyurea ,RNA, Messenger ,Molecular Biology ,DNA Primers ,chemistry.chemical_classification ,DNA synthesis ,Base Sequence ,Cell growth ,Reverse Transcriptase Polymerase Chain Reaction ,Wild type ,Genetic Variation ,Cell Biology ,DNA ,Molecular biology ,Reverse transcriptase ,Enzyme ,Ribonucleotide reductase ,chemistry ,Cell culture - Abstract
Ribonucleotide reductase (RR) is the enzyme responsible for converting nucleoside diphosphates to deoxynucleoside diphosphates, ensuring a balanced supply of deoxyribonucleotides for DNA synthesis. Expression of RR is tightly regulated, but it is affected by exogenous agents, such as hydroxyurea (HU), which inactivates the tyrosyl free radical on the small subunit of RR, R2. We have previously employed in situ reverse transcriptase (RT)-PCR to estimate expression of R2 in wild-type and HU-resistant human colon carcinoma cell lines and to correlate altered expression of R2 with changes in cell size and morphology. The current studies were undertaken to render this methodology more quantitative. Both wild-type and resistant cells were grown on partitioned glass slides and analyzed with in situ RT-PCR. Because both wildtype and resistant cells were analyzed under a single cover slip, protease digestion, reverse transcription, PCR, and color development were all performed under identical conditions. Images were analyzed with NIH Image 1.59 software. There was a highly significant correlation between expression of R2 and cell size for both sensitive and resistant cells (P 5 0.0001, for both). When cell size was compared either with expression of R2 or cell shape, however, these correlated only in wild-type cells (P 5 0.001 and 0.0001, respectively). These data demonstrate that normal cell growth in the unperturbed wild-type cell line was closely linked to expression of R2, whereas in the resistant variants which overexpress R2, these correlations were absent, suggesting that HU resistance is related to loss of linkage between R2 expression and cell growth and confirming previous data relating overexpression of R2 with multiple other changes in the cell growth repertoire. Thus, we have demonstrated for the first time a quantitative application of in situ RT-PCR. © 1999 Academic Press
- Published
- 1999
96. Molecular Targeting in Oncology
- Author
-
Howard L. Kaufman, Scott Wadler, Karen Antman, Howard L. Kaufman, Scott Wadler, and Karen Antman
- Subjects
- Drugs--Design, Cancer--Chemotherapy, Cancer--Molecular aspects, Drug targeting
- Abstract
In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice. The volume is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second section describes how clinicians are evaluating targeted therapies in specific organ systems. The third section illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth section details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more.
- Published
- 2008
97. Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy
- Author
-
Valiant Tan, Laura Benson, Avi I. Einzig, Jerry G. Kaplan, Laura Tentoramano, Scott Wadler, and Peter H. Wiernik
- Subjects
Adult ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Neutropenia ,Paclitaxel ,medicine.medical_treatment ,Malignancy ,Gastroenterology ,Subcutaneous injection ,chemistry.chemical_compound ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,medicine ,Carcinoma ,Humans ,Pharmacology (medical) ,Infusions, Intravenous ,Melanoma ,Aged ,Pharmacology ,Chemotherapy ,business.industry ,Anemia ,Immunotherapy ,Middle Aged ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Granulocyte colony-stimulating factor ,Surgery ,Oncology ,chemistry ,Toxicity ,Female ,business - Abstract
A phase I trial of a 24-hour infusion of paclitaxel was conducted to identify the maximum tolerated dose of paclitaxel with granulocyte colony-stimulating factor (G-CSF) in patients with unresectable malignancy previously untreated with chemotherapy. Nineteen patients with metastatic melanoma or non-small cell lung cancer were treated with paclitaxel administered at 250, 300, 400 mg/m2 every 3 weeks. G-CSF, 5 microg/kg was given as a daily subcutaneous injection 24 hours after the completion of the infusion. Dose limiting myelosuppression and peripheral neuropathy was observed at 400 mg/m2 and 350 mg/m2. Paclitaxel can be safely administered as a 24-hour infusion at 300 mg/m2 with G-CSF. Further studies of paclitaxel and G-CSF are recommended to determine a dose-response relationship in sensitive tumors.
- Published
- 1998
98. Expression of retinoic acid receptor-beta 2 mRNA in normal cervical epithelium and cervical squamous cell carcinoma
- Author
-
John T. Comerci, Gary L. Goldberg, Abbie L. Fields, Robert E. Gallagher, Steven J. Hallam, Scott Wadler, and Carolyn D. Runowicz
- Subjects
Cervical cancer ,Cancer Research ,Oncogene ,medicine.drug_class ,Cell ,Retinoic acid ,Cancer ,Cell cycle ,Biology ,Recurrent Cervical Carcinoma ,medicine.disease ,chemistry.chemical_compound ,medicine.anatomical_structure ,Oncology ,chemistry ,medicine ,Cancer research ,Retinoid - Abstract
Retinoids have antiproliferative effects on epithelial cells and have been used as chemopreventive and chemotherapeutic agents for several human cancers. Retinoid/interferon combinations have demonstrated activity in advanced stage cervical cancer. The objective of this study was to quantify and localize the expression of RAR-beta 2, a retinoid inducible receptor, in normal cervix and cervical squamous cell carcinoma by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and in situ RT-PCR. Specimens where obtained from 11 patients enrolled in a clinical trial to test all-trans retinoic acid (tRA) in combination with interferon-alpha 2a (IFN-alpha 2a) in the treatment of metastatic or recurrent cervical carcinoma. Expression of RAR-beta 2 in cervical carcinoma and normal cervix was measured by quantitative RT-PCR. DNA competitors were used to estimate the relative expression level of RAR-beta 2. Expression of RAR-beta 2 was examined in normal cervix by in situ RT-PCR. Expression of RAR-beta 2 in cervical carcinoma ranged from 0.33 to 1.40 with a mean of 0.89+/-0.13 vs. 1.0+/-0.13 for normal cervix (NS) with RAR-beta 2 reduced to less than or equal to 65% in five cases. Irt situ RT-PCR identified RAR-beta 2 most prominently in basal and para-basal epithelial cell layers of normal exocervix; stromal expression was markedly decreased. This is the first report to localize expression of RAR-beta 2 mRNA in normal cervical epithelium and quantify expression in normal cervix and cervical squamous cell carcinoma. Because retinoid receptors are the proximate mediators of retinoid action on gene expression, alteration of their expression or function could result in cancer development.
- Published
- 1997
99. A review of the clinical experience with irinotecan (CPT-11)
- Author
-
Robert W. Horowitz, Peter H. Wiernik, and Scott Wadler
- Subjects
Pharmacology ,Irinotecan ,Broad spectrum ,Pharmacokinetics ,Neoplasms ,Medicine ,Humans ,heterocyclic compounds ,Pharmacology (medical) ,Schedule dependency ,neoplasms ,Antitumor activity ,Clinical Trials as Topic ,biology ,business.industry ,Topoisomerase ,General Medicine ,Antineoplastic Agents, Phytogenic ,digestive system diseases ,biology.protein ,Camptothecin ,business ,medicine.drug - Abstract
Irinotecan (CPT-11) is a derivative of the chemotherapeutic agent camptothecin. CPT-11 inhibits the nuclear enzyme topoisomerase I. It has demonstrated a broad spectrum of antitumor activity in preclinical tumor model systems. Significant advances have been made toward the understanding of the pharmacokinetics and schedule dependency of this agent. CPT-11 has demonstrated significant clinical activity in the treatment of patients with gastrointestinal, pulmonary, gynecologic, and lymphoid malignancies. Further study of this agent to determine its role in combination chemotherapeutic regimens is currently underway.
- Published
- 1997
100. Pelvic exenteration for cervix cancer: would additional intraoperative interstitial brachytherapy improve survival?
- Author
-
Gary L. Goldberg, Mary Katherine Hayes, Abbie L. Fields, Scott Wadler, Patrick Anderson, Brij Sood, Carolyn D. Runowicz, and Jonathan J. Beitler
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Brachytherapy ,Perineural invasion ,Uterine Cervical Neoplasms ,Disease-Free Survival ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Cervix ,Aged ,Retrospective Studies ,Radiation ,Pelvic exenteration ,business.industry ,Interstitial brachytherapy ,Cancer ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Lymphovascular ,Surgery ,Pelvic Exenteration ,Radiation therapy ,medicine.anatomical_structure ,Oncology ,Female ,Neoplasm Recurrence, Local ,business - Abstract
OBJECTIVE Improved local control with the addition of brachytherapy to pelvic exenteration for recurrent cervical cancer has been reported to improve survival. We examined the sites of recurrence after pelvic exenteration to determine if these patients might have been salvaged by the improved local control promised by interstitial brachytherapy. We sought to identify risk factors available intraoperatively or perioperatively which might predict decreased local control. METHODS A retrospective review of 26 patients with recurrent cervical cancer who underwent total pelvic exenteration since 1988 at our institution was performed. RESULTS Overall, the mean follow-up was 29.5 months (range 6.1-81.6). Of the 26 patients, 14 had no evidence of disease (NED), 1 was alive with disease (AWD), 9 were dead of disease (DOD), and 2 died of unrelated causes (DOC). Seven of 26 patients (27%) had margins < or = 5 mm, of whom 2 were NED, 4 DOD, and 1 AWD. Seven of 26 (27%) patients had lymphovascular involvement (LVI) or perineural invasion (PNI) with clear margins. Three of the seven with LVI or PNI and clear margins were NED, and four DOD. Of the 10 failures, 9 (90%) had close margins, PNI, or LVI. CONCLUSION Our data reveal that 9 of 14 (64%) patients with close margins, LVI, or PNI were DOD or AWD, and 6 of 9 of those patients suffered local regional failure alone. Brachytherapy has the potential to cure 6 of 14 (43%) patients with these risk factors. Further study of brachytherapy at the time of pelvic extenteration is warranted.
- Published
- 1997
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.